沁恒微科创板IPO撤回:自研故事难掩毛利率下滑与研发弱化隐忧
Sou Hu Cai Jing·2026-01-30 10:02

Core Viewpoint - The recent withdrawal of IPO applications by companies like Nanjing Qinheng Microelectronics highlights challenges in the domestic semiconductor industry, particularly regarding profitability and sustainable growth [1][6]. Financial Performance - Qinheng's gross margin has shown a declining trend, dropping from 63.32% in 2022 to 57.51% in 2024, with a slight recovery to 60.46% in the first half of 2025, indicating potential issues with profitability [3][4]. - The average selling price of Qinheng's chip products decreased from 1.79 yuan in 2022 to 1.36 yuan in 2024, with significant price drops in key products such as USB chips and microcontrollers, reflecting a shift to a "price for volume" strategy due to intense market competition [3][4]. R&D Investment - Despite an increase in absolute R&D spending, the R&D expense ratio fell from 25.54% in 2022 to 15.46% in the first half of 2025, raising concerns about the company's ability to sustain high levels of technological innovation [4][6]. - Qinheng's self-research model, which emphasizes independence from external licensing, requires substantial long-term investment, and the acceptance of its self-developed ecosystem remains uncertain in a market dominated by established players [4][6]. Customer and Supplier Dynamics - The company's customer base is highly fragmented, with sales to the top five customers accounting for only 10%-15% of total sales, which limits bargaining power and increases market development costs [5]. - Conversely, the supplier base is highly concentrated, with over 75% of purchases coming from the top five suppliers, creating a "two-sided mismatch" in the supply chain [5]. Regulatory Environment - The scrutiny of companies seeking to list on the Sci-Tech Innovation Board has intensified, focusing on sustainable operational capabilities, profitability quality, and financial stability [5][6]. - Qinheng's inability to provide satisfactory responses to regulatory inquiries regarding its declining gross margin and R&D expense ratio may have contributed to its decision to withdraw its IPO application [5][6].

沁恒微科创板IPO撤回:自研故事难掩毛利率下滑与研发弱化隐忧 - Reportify